Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Pharma & Biotech
Pharma & Biotech
Can epigenome editing bypass gene size limits? Modalis’ LAMA1 data revives hope in congenital muscular dystrophy
Modalis unveils primate data showing safe LAMA1 gene activation for LAMA2-CMD. Find out what it means for CRISPR therapeutics and CMD patients.